The widespread adoption of GLP-1 medications is reshaping the nutrition industry and creating entirely new categories of companion nutrition products. Innova Market Insights data shows that 50% of current GLP-1 users in the US and Canada report consuming more protein and 46% more fibre after starting the medication, highlighting the growing relevance of nutrient-density. Alongside this, 38% report consuming more supplements (1). These shifts put nutrient-density and supplementation at the heart of GLP-1 companion nutrition, giving manufacturers a clear direction for product development.

This webinar will explore how GLP-1 medications, biomarker testing, AI and wearable technologies are influencing product development and personalised nutrition strategies. Bringing together market insight and scientific expertise, we’ll examine functional food and nutraceutical solutions to address appetite control and metabolic resilience. The session will highlight how personalised approaches can deliver more effective outcomes for muscle and bone preservation while creating new opportunities for nutrient-dense innovation across the weight management category.

Reference:

1. Innova GLP-1 & UPF Survey 2024–2026. Average of Canada and the United States. Responses from current GLP-1 users.

Are you interested in sponsoring any of our upcoming webinars?